Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK

  • The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc's SRNE Phase 2 trial evaluating COVI-DROPS in newly diagnosed COVID-19 infected patients.
  • The application was submitted as a rolling application, and the MHRA cleared the study in less than a month from Sorrento's first submission to the MHRA.
  • The application was supported by the safety data from a healthy subject study completed in the U.S., which showed a safety profile comparable to placebo with doses up to 60 mg.
  • No serious adverse effects or dose-limiting toxicities were reported, and all adverse effects were mild in severity.
  • The maximum tolerated dose was not reached.
  • The efficacy trial is a large double-blind clinical trial enrolling 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms.
  • The trial will complement the Phase 2 trial currently being started in the U.S. and a separate trial starting in Mexico.
  • COVI-DROPS is administered as an intranasal instillation in each nares and utilizes the same neutralizing antibody drug substance as COVI-AMG, the intravenous formulation.
  • The antibody is active against the original SARS-CoV-2 virus and the most prevalent viral variants of concern.
  • The results of this Phase 2 trial in the U.K. will be combined with the results of the U.S. and Mexico Phase 2 trials.
  • Price Action: SRNE shares are up 6.99% at $9.49 in the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsCovid-19COVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!